Biotech News

Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis

Arcutis Biotherapeutics (ARQT)Arcutis BiotherapeuticsClinical readout

New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment to individuals with moderate to severe atopic dermatitis Builds on existing

Related news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

Stock data

Close
27.17 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States